Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis by Poordad, Fred et al.
Research ArticleSafety of the 2D/3D direct-acting antiviral regimen in
HCV-induced Child-Pugh A cirrhosis – A pooled analysisGraphical abstracthttp://dx.doi.org/10.1016/j.jhep.2017.06.011
 2017 European Association for the Study of the Liver. Published by Elsevier B.V.AuthorsHighlights
 OBV/PTV/r ± DSV ± RBV was well tolerated in patients with
Child-Pugh A cirrhosis.
 Low rates of serious adverse events and those leading to
discontinuation of study drugs.
 Events consistent with hepatic decompensation occurred in
1.2% of patients (13/1066).
 Decompensation events occurred across the treatment
period and post treatment.
 Rates of decompensation events were comparable in treated
and untreated patients.Fred Poordad,David R.Nelson,
Jordan J. Feld, ...,NiloufarMobashery,
Fernando Tatsch,Graham R. Foster
Correspondence
poordad@txliver.com
(F. Poordad)
Lay summary
This pooled safety analysis in 1066 HCV-
infected patients with compensated
cirrhosis, receiving treatment with ombi-
tasvir, paritaprevir, and ritonavir with or
without dasabuvir, with or without rib-
avirin, shows that the rate of hepatic
decompensation events was similar to
previously reported rates in untreated
patients.J. Hepatol. 2017, 67, 700–707
Research ArticleSafety of the 2D/3D direct-acting antiviral regimen in
HCV-induced Child-Pugh A cirrhosis – A pooled analysis
Fred Poordad1,⇑, David R. Nelson2, Jordan J. Feld3, Michael W. Fried4, Heiner Wedemeyer5,
Lois Larsen6, Daniel E. Cohen6, Eric Cohen6, Niloufar Mobashery6, Fernando Tatsch6,
Graham R. Foster7
1The Texas Liver Institute/University of Texas Health, San Antonio, TX, USA; 2Division of Gastroenterology, Hepatology & Nutrition,
Department of Medicine, College of Medicine, University of Florida, Gainesville, FL, USA; 3Toronto Centre for Liver Disease,
University of Toronto, Toronto, ON, Canada; 4University of North Carolina (UNC) Liver Center, UNC School of Medicine,
Chapel Hill, NC, USA; 5Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany;
6AbbVie Inc., North Chicago, IL, USA; 7Blizard Institute of Cell and Molecular Science, Queen Mary University London, London, UKBackground & Aims: Chronic hepatitis C virus (HCV)-infected with or without ribavirin, shows that the rate of hepatic decom-
patients with cirrhosis are a high-priority population for treat- pensation events was similar to previously reported rates in
ment. To help inform the benefit–risk profile of the all-oral
direct-acting antiviral (DAA) combination regimen of ombitasvir,
paritaprevir, and ritonavir, with or without dasabuvir (OBV/PTV/r
± DSV) in patients with Child-Pugh A cirrhosis, we undertook a
comprehensive review of AbbVie-sponsored clinical trials enrol-
ling patients with Child-Pugh A cirrhosis.
Methods: Twelve phase II or III clinical trials of the 2-DAA regi-
men of OBV/PTV/r ± ribavirin (RBV) or the 3-DAA regimen of
OBV/PTV/r + DSV ± RBV that included patients with Child-Pugh
A cirrhosis were reviewed; patients who completed treatment
by November 16, 2015 were included in a pooled, post hoc safety
assessment. The number and percentage of patients with
treatment-emergent adverse events (TEAEs), serious TEAEs, and
TEAEs consistent with hepatic decompensation were reported.
Results: In 1,066 patients with Child-Pugh A cirrhosis, rates of
serious TEAEs and TEAEs leading to study drug discontinuation
were 5.3% (95% confidence interval [CI]: 4.1–6.8) and 2.2% (95%
CI: 1.4–3.2), respectively. Thirteen patients (1.2%; 95% CI:
0.7–2.1) had a TEAE that was consistent with hepatic decompen-
sation. The most frequent TEAEs consistent with hepatic decom-
pensation were ascites (n = 8), esophageal variceal hemorrhage
(n = 4), and hepatic encephalopathy (n = 2).
Conclusions: This pooled analysis in 1,066 HCV-infected patients
with Child-Pugh A cirrhosis confirms the safety of OBV/PTV/r ±
DSV ± RBV in this population. These results support the use of
OBV/PTV/r ± DSV ± RBV in this high-priority population.
Lay summary: This pooled safety analysis in 1,066 HCV-infected
patients with compensated cirrhosis, receiving treatment with
ombitasvir, paritaprevir, and ritonavir with or without dasabuvir,Journal of Hepatology 20
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Chronic hepatitis C virus (HCV) infection is characterized by pro-
gressive liver damage and fibrosis, which can lead to liver failure
or hepatocellular carcinoma.1 In 2013, an estimated 357,800 peo-
ple worldwide died from HCV-related cirrhosis, and an additional
342,500 people died from liver cancer caused by HCV.2 The bur-
den of HCV-associated liver disease is projected to continue to
increase in many countries in the coming decades.3
Cirrhosis is characterized by an initial compensated phase
during which clinical symptoms are frequently absent, followed
by a progressive decompensated phase during which clinical
findings manifest.1 Clinical symptoms and complications of
decompensated cirrhosis include jaundice, ascites, variceal hem-
orrhage, and hepatic encephalopathy.4,5 Based on three published
reports, including a systematic review of 118 studies, the esti-
mated risk of progression to decompensated cirrhosis in HCV-
infected patients with compensated cirrhosis is 66.4% per
annum.6–8 Survival rates following diagnosis of decompensated
cirrhosis are 82% at one year, decreasing to 51% at five years post
diagnosis.5 Unfortunately, there continues to be a high burden of
morbidity and mortality among patients with decompensated
cirrhosis who achieve a sustained virologic response (SVR) fol-
lowing successful treatment with direct-acting antiviral (DAA)
therapy.9
International guidelines on the treatment of chronic HCV con-
sider patients with cirrhosis as a high-priority population for
treatment with approved regimens.10 The Child-Pugh scoring
system incorporates bedside findings and laboratory variables
to help stratify the severity of cirrhotic liver disease.11 Among17 vol. 67 j 700–707
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HCV treatment-naive or treatment-experienced patients with
Child-Pugh A compensated cirrhosis, the all-oral 3-DAA regimen
of ombitasvir, paritaprevir (identified by AbbVie and Enanta),
with the pharmacokinetic enhancer ritonavir, and dasabuvir
(OBV/PTV/r + DSV), demonstrated SVR rates of 94% in genotype
(GT) 1a-infected patients, on a 24-week regimen with
ribavirin (RBV), and 100% in GT1b-infected patients, treated for
12 weeks without RBV.12,13 Among treatment-naive or
treatment-experienced GT4-infected patients with Child-Pugh A
compensated cirrhosis, the all-oral 2-DAA regimen of OBV/PTV/r
+ RBV achieved SVR rates of 96–97% with 12 weeks of treat-
ment.14,15 The safety profiles of OBV/PTV/r + DSV and OBV/PTV/r
in patients with Child-Pugh A compensated cirrhosis were
generally similar to those in patients without cirrhosis.12–21 In a
separate ongoing study of GT1-infected patients with Child-
Pugh B cirrhosis treated with OBV/PTV/r + DSV, all 11 patients
achieved sustained virologic response at post-treatment week
12 (SVR12); however, the sample size was not sufficient to fully
characterize the safety profile of this regimen in these more
advanced patients.22
Recently, the AASLD/IDSA HCV Guidance Panel published an
update to the Hepatitis C Guidance: Recommendations for Testing,
Managing, and Treating Hepatitis C Virus regarding the use of
OBV/PTV/r + DSV and OBV/PTV/r regimens.6 This update was
prompted by a change to the US Prescribing Information for
OBV/PTV/r + DSV and OBV/PTV/r, which contraindicated their
use in patients with Child-Pugh B cirrhosis.23 This change fol-
lowed post-marketing reports describing cases of hepatic decom-
pensation in patients with cirrhosis who were receiving OBV/
PTV/r + DSV. However, due to the nature of the pharmacovigi-
lance process, reported cases may lack sufficient information to
accurately characterize events and determine their relationship
to treatment regimens. Moreover, it is difficult to calculate the
frequency at which these outcomes occur, because reporting is
inconsistent and total numbers treated are not known. Analyses
of pooled safety data from clinical trials, which include systemat-
ically collected information on adverse events and baseline char-
acteristics, allow for accurate quantification of risks, albeit the
patient populations are often small and homogeneous. To better
characterize the benefit–risk profile of OBV/PTV/r ± DSV ± RBV in
patients with Child-Pugh A cirrhosis, we undertook a comprehen-
sive review of AbbVie-sponsored clinical trials that enrolled
patients with Child-Pugh A cirrhosis. We report results from this
post hoc pooled safety assessment of OBV/PTV/r ± DSV ± RBV in
HCV-infected patients with Child-Pugh A compensated cirrhosis
in 12 phase II or III trials.Patients and methods
Study design
This was a post hoc pooled safety assessment of the 2-DAA regimen of
OBV/PTV/r ± RBV and the 3-DAA regimen of OBV/PTV/r + DSV ± RBV across 12
phase II or III studies that included patients with compensated cirrhosis. The
criteria for establishing a diagnosis of compensated cirrhosis were study specific
but across studies was determined by liver biopsy, FibroScan, or serum markers
including FibroTest or aspartate aminotransferase to platelet ratio index.
Study designs have been described previously.12–15,19,24–29 All patients in the
studies provided written informed consent before any study-specific procedures
were carried out. The studies were conducted in accordance with the Interna-
tional Conference on Harmonisation guidelines, applicable regulations, and the
principles of the Declaration of Helsinki. The study protocols were approved by
each of the independent ethics committees or institutional review boards at eachJournal of Hepatology 201of the participating study sites. All authors had access to the study data and
reviewed and provided feedback on all subsequent versions of the manuscript
and made the decision to submit the manuscript for publication.
Patient population
All phase II or III clinical trials of OBV/PTV/r ± RBV or OBV/PTV/r + DSV ± RBV that
included patients with Child-Pugh A cirrhosis at screening and had patients who
had completed treatment by November 16, 2015 were included in the pooled post
hoc safety assessment. HCV-infected patients with Child-Pugh A compensated
cirrhosis who had completed or prematurely discontinued treatment with either
OBV/PTV/r ± RBV or OBV/PTV/r + DSV ± RBV were included in the safety assess-
ment (data cut-off date November 18, 2015). Although only patients with
Child-Pugh A cirrhosis at the time of screening were enrolled in these trials, a
small number of patients had an increase in Child-Pugh score between the
screening visit and the baseline visit (day 1); thus, 19 patients with Child-Pugh
B cirrhosis at baseline were included in this analysis. Patient eligibility criteria
for each of the 12 studies have been described previously.12–15,19,24–29
Study medication
Patients with HCV GT1b, GT2, or GT4 infection in the PEARL-1, AGATE-I and -II,
and GIFT-I and -II trials received OBV/PTV/r (25/150/100 mg once daily [QD])
for 12, 16, or 24 weeks. Patients with HCV GT1 infection in the TURQUOISE-II,
-III, and -IV, TOPAZ-I, -II, and -III, and TOPAZ-VA trials received OBV/PTV/r
(25/150/100 mg QD) and DSV (250 mg twice daily) for 12 or 24 weeks. Patients
in some treatment arms received RBV dosed according to body weight, with a
total daily dose of 1,000 mg (\75 kg) or 1,200 mg (P75 kg).
Safety
Data on all treatment-emergent adverse events (TEAEs) were collected from the
start of study drug administration through to 30 days after the end of treatment.
Serious adverse events (SAEs) were recorded from the time a patient signed the
informed consent through to at least 30 days after the last dose of study drug or
the end of study participation. Adverse events and SAEs were considered
treatment-emergent if they had an onset during the period from the start of study
drug administration through to 30 days after the end of treatment. This analysis
assessed the number and percentage of patients with TEAEs reported by the study
investigator thatwere consistentwith hepatic decompensation, based on adjudica-
tion of hepatic disorders according to the StandardizedMedical Dictionary for Reg-
ulatory Activities (MedDRA version 18.1) Query (SMQ) Hepatic Disorders
(broad).30 Preferred terms that could be adjudicated as a TEAE consistentwith hep-
atic decompensation are presented in Table S1. Given that PTV is an inhibitor of the
bilirubin transport protein OATP1B1 and can cause benign indirect hyperbiliru-
binemia, especially when administered with RBV, hyperbilirubinemia, in the
absence of other findings suggestive of hepatic dysfunction, was considered most
likely a result of this effect. Therefore, isolated events of jaundice or hyperbiliru-
binemiawithout concomitant evidence of hepatic decompensation or insufficiency
(e.g. increased international normalized ratio [INR], decreased albumin) were not
considered events consistent with hepatic decompensation in this analysis.
Virologic response
Plasma HCV RNA levels were determined by a central laboratory using the Roche
COBAS TaqMan real-time reverse transcriptase polymerase chain reaction (RT
PCR) assay v2.0 (lower limit of quantification [LLOQ] = 25 IU/ml) (Roche, Nutley,
NJ, USA) or Roche COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 (LLO-
Q = 15 IU/ml) (Roche, Nutley, NJ, USA).
Rates of SVR12 at (HCV RNA\LLOQ) were calculated for patients who expe-
rienced an event consistent with hepatic decompensation.
Statistical analyses
Baseline demographics and disease characteristics were summarized for patients
with cirrhosis who were treated with OBV/PTV/r ± DSV ± RBV in the selected
studies. Safety was assessed among all patients who received at least one dose
of the study drug.
An exploratory stepwise logistic regression modeling assessed predictors
(significance level = 0.10 to enter and stay inmodel) of TEAEs consistent with hep-
atic decompensation. Presence or absence of a TEAE consistent with hepatic7 vol. 67 j 700–707 701
Research Article
decompensation was the dependent variable, and baseline characteristics consid-
ered as independent variables were HCV RNA (continuous, log10 IU/ml); platelet
counts (continuous, 109/L); serum albumin (continuous, g/L); serum bilirubin
(continuous, mg/dl); INR (continuous); calculated creatinine clearance by
Cockcroft-Gault equation (continuous, ml/min); model for end-stage liver disease
(MELD) score (continuous); history of esophageal varices (yes, no); history of dia-
betes (yes, no); prior history of non-selective beta blocker use for varices (yes, no),
sex (male, female); race (black, white, Asian, other); age (continuous, years); body
mass index (continuous, kg/m2); ethnicity (Hispanic or Latino, Japanese, not His-
panic or Latino or Japanese); and prior HCV treatment status (naive, experienced).
SAS software (SAS Institute, Inc., Cary, NC, USA), for the UNIX operating sys-
tem, was used for all analyses.
For further details regarding the materials used, please refer to the Supple-
mentary material and the CTAT table.Results
Baseline characteristics
A total of 1,066 HCV-infected patients with cirrhosis were
included in the pooled safety assessment; 332 (31.1%) were trea-
ted with OBV/PTV/r ± RBV, and 734 (68.9%) were treated with
OBV/PTV/r + DSV ± RBV. Most patients (864; 81.1%) received
RBV. Baseline demographics and disease characteristics are pre-
sented in Table 1. Overall, 346 (32.5%) were female, 185 (17.4%)
were P65 years old, and the median body mass index was
27.2 kg/m2. The majority of patients (859; 80.6%) had a baseline
HCV RNA P800,000 IU/ml. Most patients (874; 82.0%) were
infected with HCV GT1. Approximately half of the patients
(480; 45.0%) were HCV treatment-naive. The majority of patients
(891; 85.6%) had a baseline Child-Pugh score of five, 130 (12.5%)
had a score of six, and 19 (1.8%) had a score of seven or eight.
Baseline platelet counts\50 and\90 cells109/L were recorded
in nine (0.8%) and 191 (17.9%) patients, respectively. Few patients
had a prior history of ascites (3; 0.3%), hepatic encephalopathy (4;
0.4%), or esophageal varices (91; 8.5%).
Safety
Overall rates of serious TEAEs and TEAEs leading to study drug
discontinuation were 5.3% (95% confidence interval [CI]: 4.1–
6.8) and 2.2% (95% CI: 1.4–3.2), respectively. There were no obvi-
ous differences in these rates among the different treatment
groups, except that both serious TEAEs and TEAEs leading to
study drug discontinuation were less frequent in the 62 patients
who received OBV/PTV/r + DSV without RBV (Table 2). In total, 13
patients (1.2%; 95% CI: 0.7–2.1) had a TEAE reported by the study
investigator that was consistent with hepatic decompensation;
11 of the 13 patients (85%) received RBV. Rates of individual
events were low (\1%) (Table 2). Two TEAEs consistent with hep-
atic decompensation (liver failure and hepatorenal syndrome),
which occurred in the same patient, were considered to poten-
tially relate to the study drug by the study investigator. Two iso-
lated cases of hyperbilirubinemia and one case of jaundice were
potentially related to the study drug. Five of the 13 patients expe-
rienced serious TEAEs consistent with hepatic decompensation,
including four patients with esophageal variceal hemorrhage
and one patient who developed liver failure and hepatorenal syn-
drome. A 59-year-old female patient who developed liver failure
and hepatorenal syndrome discontinued the study drug after
56 days of treatment and was hospitalized two days later. No
information is available on the clinical outcome or virologic
response for this patient because she was subsequently lost to702 Journal of Hepatology 201follow-up. An additional patient experienced a non-serious event
of ascites after eight days of treatment, but died eight days later
due to multiple organ failure as a result of community-acquired
pneumonia. Five patients (38.5%) with a TEAE consistent with
hepatic decompensation discontinued treatment prematurely.
Day of onset of TEAEs consistent with hepatic decompensa-
tion is presented in Fig. 1. The onset of these events was spread
across the treatment period and 30 days post-treatment. Clinical
outcomes for patients with TEAEs consistent with hepatic decom-
pensation are given in Table 3. These events resolved in nine
patients (69.2%), including six patients who continued treatment
with the study drug. Clinical summaries for the 13 patients with
TEAEs consistent with hepatic decompensation are presented in
Table S2.
Change in Child-Pugh score based on changes in total bilirubin values
Among the 1,021 patients with a Child-Pugh score of five or six at
baseline, 7.3% of patients (65/891) with a baseline Child-Pugh
score of five and 36.2% of patients (47/130) with a baseline
Child-Pugh score of six experienced an increase in their Child-
Pugh score to seven or greater due to increased total bilirubin
alone during treatment with OBV/PTV/r ± DSV ± RBV.
Baseline factors associated with TEAEs consistent with hepatic
decompensation
Compared with patients who did not experience a TEAE consis-
tent with hepatic decompensation, those patients who did expe-
rience such an event had a higher frequency of baseline Child-
Pugh score of six or greater, platelet count\90109 cells/L, and
serum albumin\3.5 g/dl, all characteristics consistent with more
advanced liver disease (Table 4).
The exploratory stepwise logistic regression analysis demon-
strated that lower baseline albumin, prior history of non-
selective beta blocker use for varices and lower baseline HCV
RNA were independently associated with TEAEs consistent with
hepatic decompensation (p\0.05; Table 5).
Virologic response
There were no confirmed virologic relapses or breakthroughs
among the 13 patients who experienced a TEAE consistent with
hepatic decompensation. Ten of these 13 patients (77%) achieved
SVR; this number includes one patient who achieved SVR four
weeks after the end of treatment but who had not reached
post-treatment week 12 at the time of analysis. Among the
patients who did not achieve SVR, one discontinued treatment
prematurely, one was lost to follow-up, and one died prior to
post-treatment week 12 (due to multiple organ failure as a result
of community-acquired pneumonia).Discussion
In this pooled analysis of 1,066 HCV-infected patients with Child-
Pugh A cirrhosis, treatment with OBV/PTV/r ± DSV ± RBV was
well-tolerated, demonstrated by low rates of SAEs (5.3%) and
TEAEs leading to study drug discontinuation (2.2%). In total, 13
out of 1,066 patients (1.2%) experienced an event that was
consistent with hepatic decompensation. Our observations are7 vol. 67 j 700–707
Table 1. Baseline demographics and patient characteristics.
Characteristic OBV/PTV/r
n = 140
OBV/PTV/r + RBV
n = 192
OBV/PTV/r + DSV
n = 62
OBV/PTV/r + DSV + RBV
n = 672
Total
N = 1,066
Women, n (%) 65 (46.4) 49 (25.5) 23 (37.1) 209 (31.1) 346 (32.5)
Age (years), median (range) 59.0 (38.0–76.0) 56.0 (32.0–81.0) 61.0 (26.0–78.0) 57.0 (21.0–79.0) 58.0 (21.0–81.0)
BMI (kg/m2), median (range) 25.8 (15.0–38.4) 27.8 (18.9–47.8) 27.0 (18.0–42.3) 27.4 (17.0–51.7) 27.2 (15.0–51.7)
Race, n (%)
White 96 (68.6) 154 (80.2) 54 (87.1) 628 (93.5) 932 (87.4)
Black or African American 0 23 (12.0) 7 (11.3) 31 (4.6) 61 (5.7)
Asian 42 (30.0) 14 (7.3) 0 11 (1.6) 67 (6.3)
Other 2 (1.4) 1 (0.5) 1 (1.6) 2 (0.3) 6 (0.6)
Ethnicity
Hispanic or Latino 3 (2.1) 3 (1.6) 3 (4.8) 84 (12.5) 93 (8.7)
Japanese 41 (29.3) 10 (5.2) 0 0 51 (4.8)
No ethnicity 96 (68.6) 179 (93.2) 59 (95.2) 588 (87.5) 922 (86.5)
HCV RNA, n (%)
P800,000 IU/ml 116 (82.9) 135 (70.3) 56 (90.3) 522 (82.1) 859 (80.6)
Viral load (log10 IU/ml, median (range) 6.5 (4.5–7.7) 6.2 (2.3–7.2) 6.7 (3.8–7.5) 6.4 (2.9–7.7) 6.4 (2.3–7.7)
HCV genotype, n (%)
1 140 (100) 0 62 (100) 672 (100) 874 (82.0)
2 0 10 (5.2) 0 0 10 (0.9)
4 0 182 (94.8) 0 0 182 (17.1)
IL28B genotype, n (%)*
CC 39 (27.9) 25 (19.1) 10 (16.1) 128 (19.1) 202 (20.1)
CT 81 (57.9) 71 (54.2) 37 (59.7) 404 (60.2) 593 (59.1)
TT 20 (14.3) 35 (26.7) 15 (24.2) 139 (20.7) 209 (20.8)
Missing 0 61 0 1 62
Prior therapy (IFN-based), n (%)
Treatment-naive 55 (39.3) 93 (48.4) 28 (45.2) 304 (45.2) 480 (45.0)
Child-Pugh score, n (%)*
5 119 (85.0) 168 (87.5) 48 (77.4) 556 (85.9) 891 (85.6)
6 17 (12.1) 19 (9.9) 12 (19.4) 82 (12.7) 130 (12.5)
[6y 4 (2.9) 4 (2.1) 2 (3.2) 9 (1.4) 19 (1.8)
Other 0 1 (0.5) 0 0 1 (0.1)
Missing 0 0 0 25 25
Platelet count, n (%)*
\50109 cells/L 0 2 (1.0) 0 7 (1.0) 9 (0.8)
\90109 cells/L 31 (22.1) 34 (17.7) 13 (21.0) 113 (16.8) 191 (17.9)
Missing 0 0 0 1 1
Albumin, n (%)
\3.5 g/dl 14 (10.0) 11 (5.7) 10 (16.1) 53 (7.9) 88 (8.3)
Total bilirubin (mg/dl), median (range) 0.76 (0.23–3.33) 0.70 (0.18–2.57) 0.80 (0.29–2.51) 0.76 (0.18–3.40) 0.76 (0.18–3.40)
INR (ratio), median (range) 1.10 (0.90–1.50) 1.08 (0.90–2.60) 1.10 (0.90–1.30) 1.07 (0.85–3.42) 1.09 (0.85–3.42)
MELD score, median (range) 7.50 (6.43–15.52) 7.50 (6.43–17.49) 7.88 (6.43–12.57) 7.50 (6.43–20.20) 7.50 (6.43–20.20)
Creatinine clearance, n (%)
\60 ml/min 9 (6.4) 3 (1.6) 8 (12.9) 11 (1.6) 31 (2.9)
History of diabetes, n (%) 32 (22.9) 52 (27.1) 12 (19.4) 121 (18.0) 217 (20.4)
History of ascites, n (%) 1 (0.7) 0 1 (1.6) 1 (0.1) 3 (0.3)
History of hepatic encephalopathy, n (%) 0 0 0 4 (0.6) 4 (0.4)
History of esophageal varices, n (%) 15 (10.7) 11 (5.7) 8 (12.9) 57 (8.5) 91 (8.5)
OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; DSV, dasabuvir; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; IL28B, interleukin-28B;
IFN, interferon; INR, international normalized ratio; MELD, model for end-stage liver disease.
* Percentages are based on the number of patients with available data (ie, patients with missing data are not included in the calculation).
y Child-Pugh scores of 7 or 8.
 Child-Pugh score of 3.
JOURNAL OF HEPATOLOGYfurther supported by a recent real-world meta-analysis among
5,158 patients receiving treatment with OBV/PTV/r ± DSV ± RBV,
63% of whom (n = 3,240) had cirrhosis, showing that in the five
studies with reported data (n = 3,440), a total of 33 patients
reported hepatic decompensation (0.96%; 95% CI 0.68–1.34); in
the seven studies with reported data (n = 2,370), 74 patients
(3.12%) reported SAEs; and in the 12 studies with reported data
(n = 5,170), 129 patients (2.5%) discontinued drug for any
reason.31Journal of Hepatology 201TEAEs consistent with hepatic decompensation have been
reported in patients with advanced liver disease, treated with a
number of DAA regimens. These events tend to occur at various
times during treatment and even post treatment, as seen in the
present analysis, making it difficult to establish a causal relation-
ship with specific DAA treatments.32–37 Given that hepatic
decompensation events have been reported in association with
multiple classes of DAAs, it is unclear whether direct toxicity of
DAAs, including protease inhibitors, is responsible for these7 vol. 67 j 700–707 703
Table 2. Treatment-emergent adverse events reported by the study investigator.
OBV/PTV/r
n = 140
OBV/PTV/r + RBV
n = 192
OBV/PTV/r + DSV
n = 62
OBV/PTV/r + DSV + RBV
n = 672
Total
N = 1,066
Serious TEAE, n (%) 7 (5.0) 10 (5.2) 1 (1.6) 38 (5.7) 56 (5.3)
Discontinuation of study drug due to a TEAE, n (%) 4 (2.9) 0 0 19 (2.8) 23 (2.2)
TEAE of interest,* n (%)
Any eventy 2 (1.4) 4 (2.1) 0 7 (1.0) 13 (1.2)
Ascites 2 (1.4) 2 (1.0) 0 4 (0.6) 8 (0.8)
Esophageal varices hemorrhage 1 (0.7) 2 (1.0) 0 1 (0.1) 4 (0.4)
Hepatic failure 0 0 0 1 (0.1) 1 (\0.1)
Hepatorenal syndrome 0 0 0 1 (0.1) 1 (\0.1)
Hypoalbuminemia 0 1 (0.5) 0 0 1 (\0.1)
Hepatic encephalopathy 0 1 (0.5) 0 1 (0.1) 2 (0.2)
Jaundice 0 1 (0.5) 0 2 (0.3) 3 (0.3)
Increased bilirubin 0 1 (0.5) 0 0 1 (0.1)
OBV, ombitasvir; PTV, paritaprevir; r, ritonavir; RBV, ribavirin; DSV, dasabuvir; TEAE, treatment-emergent adverse event.
* TEAE consistent with hepatic decompensation from adjudication of hepatic disorders according to the Standardized Medical Dictionary for Regulatory Activities
(MedDRA) Query (SMQ) Hepatic Disorders (broad).
y A total of 18 adverse events consistent with hepatic decompensation occurred in 13 patients; one patient had two episodes of ascites.
 Events of jaundice (n = 3) and increased bilirubin (n = 1) were reported in three subjects with hepatic decompensation events.
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Fig. 1. Cumulative onset of treatment-emergent adverse events consistent
with hepatic decompensation by planned treatment duration. Circles repre-
sent treatment-emergent adverse events (TEAEs) of interest among patients
receiving 12 weeks of treatment, triangles represent TEAEs of interest among
patients receiving 16 weeks of treatment, and squares represent TEAEs of interest
among patients receiving 24 weeks of treatment. One patient had two episodes of
ascites, one at day 142 and one at day 186. *TEAE consistent with hepatic
decompensation from adjudication of hepatic disorders according to the
Standardized Medical Dictionary for Regulatory Activities (MedDRA) Query
(SMQ) Hepatic Disorders (broad).
Table 3. Clinical outcomes in patients with treatment-emergent adverse
events consistent with hepatic decompensation.
TEAE of interest,* n (%) OBV/PTV/r ± DSV ± RBV
N = 13
TEAE(s) resolvedy 9 (69.2)
TEAE(s) ongoing 2 (15.4)
Death§ 1 (7.7)
Information not available 1 (7.7)
TEAE, treatment-emergent adverse event; OBV, ombitasvir; PTV, paritaprevir;
r, ritonavir; DSV, dasabuvir; RBV, ribavirin.
* TEAE consistent with hepatic decompensation from adjudication of hepatic
disorders according to the Standardized Medical Dictionary for Regulatory
Activities (MedDRA) Query (SMQ) Hepatic Disorders (broad).
y TEAEs resolved in six patients while continuing treatment and in three patients
post discontinuation.
 At least one event was ongoing at the end of the follow-up or data cut-off date.
§ One patient died as a result of community-acquired pneumonia, leading to
multiple organ failure.
Research Articleevents.38 Another possibility is that hepatic decompensation
events reported with DAAs are unrelated to therapy and are
instead simply part of the natural history of advanced liver dis-
ease caused by HCV infection.38 This theory is consistent with
the findings of the present analysis, in which the rate of TEAEs
consistent with hepatic decompensation is within the range for
the previously reported annual risk of up to 6.4% for hepatic
decompensation in HCV-infected patients with compensated cir-
rhosis.6–8 However, prescribing information for currently avail-
able regimens containing an HCV NS3-4A protease inhibitor
typically contraindicate or recommend against their use in
patients with Child-Pugh B or C cirrhosis. More data are needed
to establish whether there is a causal relationship between this
and other classes of DAA and events of hepatic decompensation.704 Journal of Hepatology 201Importantly, many of the events consistent with hepatic
decompensation were self-limiting and improved without treat-
ment interruption, or occurred at time points not typically asso-
ciated with drug toxicity. Ascites (n = 8), variceal hemorrhage
(n = 4), and encephalopathy (n = 2) were the most frequently
reported events; there was one case of hepatic failure with hep-
atorenal syndrome. Five of the 13 patients with TEAEs consistent
with hepatic decompensation discontinued study drug and 10
achieved an SVR. There was one reported death due to multiple
organ failure as a result of community-acquired pneumonia.
Overall, 11% of patients in this cohort experienced an increase
in Child-Pugh score to seven or greater during treatment with
OBV/PTV/r ± DSV ± RBV, owing to increased total bilirubin alone.
Most TEAEs consistent with hepatic decompensation were
considered by the investigator causally unrelated to study drug
administration. Two cases, an event of hypoalbuminemia and a
case of ascites, occurred in patients with associated bacterial
infections, while a second case of ascites occurred in a patient
who was later diagnosed with hepatocellular carcinoma.
In the present analysis, baseline characteristics consistent
with advanced liver disease were enriched in the group of
patients who experienced a TEAE consistent with hepatic decom-7 vol. 67 j 700–707
Table 4. Baseline demographics of patients with or without a treatment-emergent adverse event consistent with hepatic decompensation.
Characteristic TEAE of interest*
No
n = 1,053
Yes
n = 13
Female sex, n (%) 341 (32.4) 5 (38.5)
Age (years), median (range) 57 (21–81) 60 (28–72)
BMI (kg/m2), median (range) 27.2 (15.0–51.7) 26.7 (23.9–37.2)
Race, n (%)
White 920 (87.4) 12 (92.3)
Black or African American 60 (5.7) 1 (7.7)
Asian 67 (6.4) 0
Other 6 (0.6) 0
Ethnicity
Hispanic or Latino 93 (8.8) 0
Japanese 51 (4.8) 0
No ethnicity 909 (86.3) 13 (100)
HCV RNA, n (%)
P800,000 IU/ml 851 (80.8) 8 (61.5)
HCV genotype, n (%)
1 865 (82.1) 9 (69.2)
2 10 (0.9) 0
4 178 (16.9) 4 (30.8)
IL28B genotype, n (%)
CC 198 (20.0) 4 (33.3)
CT 585 (59.0) 8 (66.7)
TT 209 (21.1) 0
Missing 61 1
Prior therapy (IFN-based), n %
Treatment-naive 471 (44.7) 9 (69.2)
Child-Pugh score, n (%)
5 886 (86.2) 5 (38.5)
6 122 (11.9) 8 (61.5)y
[6 19 (1.8) 0
Missing or other 25 0
Platelet count, n (%)
\50 cells109/L 9 (0.9) 0
\90 cells109/L 185 (17.6) 6 (46.2)
Missing 1 0
Albumin, n (%)
\3.5 g/dl 83 (7.9) 5 (38.5)§
Total bilirubin (mg/dl), median (range) 0.76 (0.18–3.40) 1.05 (0.40–1.75)
INR (ratio), median (range) 1.09 (0.85–3.42) 1.10 (0.90–1.32)
MELD score, median (range) 7.50 (6.43–20.20) 9.08 (6.43–11.66)
Creatinine clearance, n (%)
\60 ml/min 31 (2.9) 0
History of diabetes, n (%) 214 (20.3) 3 (23.1)
History of ascites, n (%) 3 (0.3) 0
History of hepatic encephalopathy, n (%) 4 (0.4) 0
History of esophageal varices, n (%) 88 (8.4) 3 (23.1)
TEAE, treatment-emergent adverse event; BMI, body mass index; HCV, hepatitis C virus; RNA, ribonucleic acid; IL28B, interleukin-28B; IFN, interferon; INR, international
normalized ratio; MELD, model for end-stage liver disease.
* TEAE consistent with hepatic decompensation from adjudication of hepatic disorders according to the Standardized Medical Dictionary for Regulatory Activities
(MedDRA) Query (SMQ) Hepatic Disorders (broad).
y Child-Pugh score P6 vs. 5 or missing/other; p\0.0003.
 Platelet count\90 cells  109/L vs. P90 cells  109/L or missing; p = 0.0173.
§ Albumin\35 g/L vs. P35 g/L; p = 0.0026.
JOURNAL OF HEPATOLOGYpensation, compared with those who did not. Low baseline albu-
min (63.6 g/dl), HCV RNA (66.4 log10 IU/ml), and prior history of
non-selective beta blocker use for varices were identified as pre-
dictive factors associated with TEAEs consistent with hepatic
decompensation. The association between low baseline HCV
RNA levels and TEAEs consistent with hepatic decompensationJournal of Hepatology 201is consistent with previous observations that low serum HCV
RNA levels may be a surrogate marker for advanced cirrhosis.39,40
A limitation of this analysis is that only 13 patients with
TEAEs consistent with hepatic decompensation were identified,
and the analysis therefore had low power to identify predictors
of hepatic decompensation. Results of the stepwise logistic
regression analysis should therefore be interpreted with caution.7 vol. 67 j 700–707 705
Table 5. Patient characteristics associated with increased risk of treatment-emergent adverse events consistent with hepatic decompensation.*
Odds ratio [95% CI] p value
Baseline albumin level (continuous, g/L) 0.85 [0.76, 0.96] 0.008
Baseline HCV RNA (continuous, log10 IU/ml) 0.39 [0.22, 0.72] 0.003
Prior history of non-selective beta blockers for varices (yes, no) 4.86 [1.19, 19.83] 0.028
CI, confidence interval; HCV, hepatitis C virus; RNA, ribonucleic acid; INR, international normalized ratio; MELD, model for end-stage liver disease; BMI, body mass index.
* Independent baseline variables that were considered in stepwise logisitic regression modeling (significance level = 0.10 to enter and stay in model): HCV RNA
(continuous, log10 IU/ml); platelet counts (continuous, 109/L); albumin (continuous, g/L); bilirubin (continuous, mg/dl); INR (ratio); creatinine clearance (continuous, ml/
min); MELD score (continuous); history of esophageal varices (yes, no); history of diabetes (yes, no); prior medical history of non-selective beta blocker for varices (yes, no),
sex (male, female); race (black, white, Asian, other); age (continuous, years); BMI (continuous, kg/m2); ethnicity (Hispanic or Latino, Japanese, not Hispanic or Latino); and
prior treatment status (naive, experienced).
Research ArticleDespite these limitations and the fact that these events occurred
at a low rate in this analysis, our results suggest caution should
be exercised when considering the use of OBV/PTV/r with or
without DSV in patients with signs of advanced cirrhosis.Conclusion
In summary, this pooled analysis in 1,066 HCV-infected patients
demonstrates that among patients with Child-Pugh A cirrhosis
treated with OBV/PTV/r ± DSV ± RBV, the rate of TEAEs consistent
with hepatic decompensation was 1.2%, which is lower than the
rate of hepatic decompensation previously reported in the
untreated cirrhotic population. Patients with prior evidence of
advanced cirrhosis were more likely to experience such TEAEs.
These data support the use of OBV/PTV/r ± DSV ± RBV in patients
with cirrhosis, but these regimens should be avoided in patients
with a history of hepatic decompensation.Financial support
AbbVie sponsored the study, contributed to its design, partici-
pated in the collection, analysis, and interpretation of the data,
and in the writing, reviewing, and approval of the publication.Conflict of interest
F. Poordad; Grant/Research Support: AbbVie, Achillion Pharma-
ceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehrin-
ger Ingelheim, BMS, Genentech, Gilead, GlaxoSmithKline,
GlobeImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals,
Intercept Pharmaceuticals, Janssen, Medarex, Medtronic, Merck,
Novartis, Santaris Pharmaceuticals, Scynexis Pharmaceuticals,
Vertex Pharmaceuticals, ZymoGenetics; Speaker: Gilead, Kad-
mon, Merck, Onyx/Bayer, Genentech, GlaxoSmithKline, Salix, Ver-
tex; Consultant/Advisor: AbbVie, Achillion Pharmaceuticals,
Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingel-
heim, BMS, Gilead, GlaxoSmithKline, GlobeImmune, Idenix, Mer-
ck, Novartis, Tibotec/Janssen, Theravance, Vertex. D.R. Nelson;
Advisory Committees or Review Panels: Merck; Grant/Research
Support: Abbott, BMS, Boehringer Ingelheim, Gilead, Genentech,
Merck, Bayer, Idenix, Vertex, Janssen. J.J. Feld; Grant/Research
Support: AbbVie, Boehringer Ingelheim, Gilead, Janssen, Merck;
Scientific Consulting/Advisory Board: AbbVie, BMS, Gilead, Jans-
sen, Merck, Theravance. M.W. Fried; Research Grants: AbbVie,
BMS, Gilead, Merck; Consulting: AbbVie, BMS, Gilead, Merck. H.706 Journal of Hepatology 201Wedemeyer; Honoraria for Consulting/Speaking: Abbott, AbbVie,
Achillion, BMS, Boehringer Ingelheim, Gilead, GSK, ITS, Janssen,
Merck, Novartis, Roche, Roche Diagnostics, Siemens, Transgene;
Grant Support: Abbott, BMS, Merck, Novartis, Roche. L. Larsen;
AbbVie employee and may hold AbbVie stock or options. D.E.
Cohen; AbbVie employee and may hold AbbVie stock or options.
E. Cohen; AbbVie employee and may hold AbbVie stock or
options. N. Mobashery; AbbVie employee and may hold AbbVie
stock or options. F. Tatsch; AbbVie employee and may hold Abb-
Vie stock or options. G.R. Foster; Grant/Research Support: AbbVie,
BMS, Merck, Roche/Genentech, Gilead, Novartis, Janssen; Consul-
tant/Advisor: AbbVie, Vertex, BMS, Merck, Roche/Genentech,
Gilead, GSK, Janssen, Virco, Novartis.Authors’ contributions
All authors had access to the study data and reviewed and pro-
vided feedback on all subsequent versions of the manuscript
and made the decision to submit the manuscript for
publication.
Acknowledgement
The authors wish to thank Rebecca Reindel for contributing to the
interpretation of results and review of the manuscript. Medical
writing support was provided by Andrew Kerr of Medical Expres-
sions, funded by AbbVie.Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.jhep.2017.06.
011.References
[1] Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection.
Int J Med Sci 2006;3:47–52.
[2] GBD 2013 Mortality and causes of death collaborators. Global, regional, and
national age-sex specific all-cause and cause-specific mortality for 240
causes of death, 1990-2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet 2015;385:117–171.
[3] Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, et al. The
present and future disease burden of hepatitis C virus (HCV) infection with
today’s treatment paradigm. J Viral Hepat 2014;21:34–59.
[4] Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications:
evidence based treatment. World J Gastroenterol 2014;20:5442–5460.7 vol. 67 j 700–707
JOURNAL OF HEPATOLOGY
[5] Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al.
Natural history of decompensated hepatitis C virus-related cirrhosis. A study
of 200 patients. J Hepatol 2004;40:823–830.
[6] AASLD-IDSA Guidance Panel. HCV guidance: Recommendations for testing,
managing, and treating hepatitis C September 16, 2016; 2016.
[7] Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review:
outcome of compensated cirrhosis due to chronic hepatitis C infection.
Aliment Pharmacol Ther 2010;32:344–355.
[8] D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic
indicators of survival in cirrhosis: a systematic review of 118 studies.
J Hepatol 2006;44:217–231.
[9] Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al.
Outcomes after successful direct-acting antiviral therapy for patients with
chronic hepatitis C and decompensated cirrhosis. J Hepatol
2016;65:741–747.
[10] AASLD/IDSA HCV guidance panel. HCV guidance: Recommendations for
testing, managing, and treating hepatitis C. Hepatology 2015;62:932–954.
[11] Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection
of the oesophagus for bleeding oesophageal varices. Br J Surg
1973;60:646–649.
[12] Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained
virologic response of 100% in HCV genotype 1b patients with cirrhosis
receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol
2016;64:301–307.
[13] Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-
450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
N Engl J Med 2014;370:1973–1982.
[14] Esmat GE, Doss WH, Qaqish RB, Waked I, Shiha GE, Yosry A, et al. Efficacy
and safety of co-formulated ombitasvir/paritaprevir/ritonavir with ribavirin
in adults with chronic HCV genotype 4 infection in Egypt (AGATE-II).
Hepatology 2015;62:560A.
[15] Asselah T, Hassanein TI, Roula B, Qaqish RB, Feld JJ, Hezode C, et al. Efficacy
and safety of ombitasvir/paritaprevir/ritonavir co-administered with rib-
avirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis
(AGATE-I). Hepatology 2015;62:563A–564A.
[16] Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-
ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med
2014;370:1983–1992.
[17] Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al.
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with rib-
avirin. N Engl J Med 2014;370:1604–1614.
[18] Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al.
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100%
sustained virologic response with or without ribavirin in treatment-expe-
rienced patients with HCV genotype 1b infection. Gastroenterology
2014;147:359–365.
[19] Hezode C, Asselah T, Reddy K, Hassanein T, Berenguer M, Fleischer-
Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or
without ribavirin in treatment-naive and treatment-experienced patients
with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised,
open-label trial. Lancet 2015;385:2502–2509.
[20] Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al.
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
N Engl J Med 2014;370:1594–1603.
[21] Reau N, Poordad F, Enejosa J, Siddique A, Aguilar IH, Lalezari PJ, et al.
Preliminary safety and efficacy results from TOPAZ-II: a phase 3b study
evaluating long-term clinical outcomes in HCV genotype 1-infected patients
receiving ombitasvir/paritaprevir/r and dasabuvir +/-ribavirin. Hepatology
2015;62:732A.
[22] Mantry PS, Hanson J, Trinh R, Ramji A, Frederick L, Abunimeh M, et al.
Ombitasvir/paritaprevir/r and dasabuvir with ribavirin for HCV genotype 1
patients with decompensated cirrhosis. Hepatology 2015;62:568A–569A.Journal of Hepatology 201[23] AbbVie. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets;
dasabuvir tablets), co-packaged for oral use US Prescribing Information
2016; 2016.
[24] ClinicalTrials.gov. A study to evaluate chronic hepatitis C infection in
cirrhotic adults with genotype 1b infection (TURQUOISE-IV) 2015; 2016.
[25] ClinicalTrials.gov. Study to evaluate the efficacy and safety of ABT-450/
ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese adults with genotype 2
chronic hepatitis C virus (HCV) infection (GIFT II) 2015; 2016.
[26] ClinicalTrials.gov. A study to evaluate the efficacy and safety of three
experimental drugs in adults with hepatitis C virus infection, who are either
treatment-naive or treatment-experienced in Brazil 2016; 2016.
[27] ClinicalTrials.gov. A study to evaluate the safety and efficacy of
ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin
in US veterans with genotype 1 chronic hepatitis C virus infection 2016;
2016.
[28] Dumas EO, Enejosa J, Ball G, Hu YB, Co M, Pothacamury RK, et al. Phase 3B
studies to assess long-term clinical outcomes in HCV GT1-infected patients
treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or with-
out ribavirin. J Hepatol 2015;62:S855.
[29] Kumada H, Chayama K, Rodrigues Jr L, Suzuki F, Ikeda K, Toyoda H, et al.
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C
virus genotype 1b-infected Japanese patients with or without cirrhosis.
Hepatology 2015;62:1037–1046.
[30] International council for harmonisation of technical requirements for
pharmaceuticals for human use (ICH). Medical dictionary for regulatory
activities 2016; 2016.
[31] Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK et al.
Meta-analysis of the real-world effectiveness of ombitasvir/paritaprevir/
ritonavir ± dasabuvir ± ribavirin in patients with HCV genotype 1 or 4
infection. EASL Special Conference, New perspectives in hepatitis C virus
infection – Roadmap for the cure. Paris, France, September 23–24, 2016;
Poster 219.
[32] Curry MP, O’Leary JG, Bzowej NH, Muir AJ, Korenblat K, Fenkel JM, et al.
Sofosbuvir and velpatasvir for HCV in patients with decompensated
cirrhosis. N Engl J Med 2015;373:2618–2628.
[33] Charlton M, Everson G, Flamm S, Kumar P, Landis C, Brown Jr R, et al.
Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection with
advanced liver disease. Gastroenterology 2015;149:649–659.
[34] Saxena V, Nyberg L, Pauly M, Dasgupta A, Nyberg A, Piasecki B, et al.
Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected
patients with compensated and decompensated cirrhosis. Hepatology
2015;62:715–725.
[35] Kalafateli M, Dusheiko G, Manousou P. Clinical decompensation after
achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with
recurrent HCV post-liver transplant. J Gastrointestin Liver Dis
2015;24:257–258.
[36] Stine JG, Intagliata N, Shah NL, Argo CK, Caldwell SH, Lewis JH, et al. Hepatic
decompensation likely attributable to simeprevir in patients with advanced
cirrhosis. Dig Dis Sci 2015;60:1031–1035.
[37] Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, et al.
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin
use. J Hepatol 2016;64:234–238.
[38] Hoofnagle JH. Hepatic decompensation during direct-acting antiviral ther-
apy of chronic hepatitis C. J Hepatol 2016;64:763–765.
[39] Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low
HCV replication levels in end-stage hepatitis C virus-related liver disease.
J Hepatol 1999;31:593–597.
[40] Puoti C, Castellacci R, Bellis L, Montagnese R, Corvisieri P, Festuccia P,
et al. Hepatitis C virus RNA quantitation in hepatic veins and peripheral
blood in patients with liver cirrhosis: evidence for low level intrahepatic
hepatitis C virus replication in advanced liver disease. Dig Liver Dis
2002;34:802–807.7 vol. 67 j 700–707 707
